Position of the Transparency Council – Remsima (infliximab)

At its meeting on 24 February 2025, the Transparency Council adopted position No. 26/2025 on the evaluation of the drug Remsima (infliximab) within the framework of the drug program B.47. “Treatment of patients with moderate to severe plaque psoriasis (ICD-10 L40.0)”.

Publication of the position >>